DJ4

DJ4 is a novel small molecule multi-kinase inhibitor specifically targeting Rho-associated protein kinase 1 and 2 (ROCK1/2) and myotonic dystrophy kinase-related Cdc42-binding kinase alpha and beta (MRCKα/β). Developed by researchers at the Penn State University College of Medicine, DJ4 is being investigated for the treatment of acute myeloid leukemia (AML). By inhibiting ROCK, DJ4 disrupts the phosphorylation of downstream targets such as myosin light chain 2 (MLC2) and the myosin-binding subunit of myosin light chain phosphatase (MYPT), which are essential for cytoskeletal dynamics and cell survival. Preclinical studies have demonstrated that DJ4 induces dose-dependent cytotoxic and pro-apoptotic effects in human AML cell lines and primary patient cells while largely sparing normal hematopoietic cells. In murine models, administration of DJ4 has been shown to reduce disease progression and improve overall survival, marking it as a promising candidate for further clinical investigation.

Other names

(5Z)-2-5-(1H-pyrrolo[2,3-b]pyridine-3-ylmethylene)-1,3-thiazol-4(5H)-one